Collaborations | ORBIT
ORBIT - Opportunities in Receptor Biology for Industrial Translation
ORBIT is a new collaborative R&D initiative launched by Heptares Therapeutics in January 2016.
Heptares has committed up to £5 million over three years to fund this initiative, which will see the company collaborate with leading academic groups and emerging biotechnology companies, leveraging the expertise of collaborators to seek out new links between GPCRs and diseases and to develop a better understanding of disease biology relating to a broad range of GPCR targets, thus creating transformative medicines.
The first collaboration under this new initiative, signed in January 2016, is with academics at Imperial College London’s National Heart and Lung Institute (NHLI) and is focused on an orphan receptor that is implicated in a range of immune disorders including asthma and inflammatory bowel disease.
In January 2017, Heptares launched a new collaboration with the University of Cambridge focused on the discovery of novel molecules that target and modulate the apelin receptor, a GPCR found on the surface of cells in the lung, heart and vascular system, and implicated in a range of cardiovascular diseases.
Heptares welcomes applications for collaborations linking GPCRs to disease. Please contact us at email@example.com